logo-loader
RNS
viewHemoGenyx Pharmaceuticals

Hemogenyx scientific advisor receives Lasker Award

/**/ h1{margin-top:24.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;line-height:107%;font-size:24.0pt;font-family:"Calibri","sans-serif";}h2{margin-top:18.0pt;margin-right:0cm;margin-bottom:4.0pt;margin-left:0cm;line-height:107%;font-size:18.0pt;font-family:"Calibri","sans-serif";}h3{margin-top:14.0pt;margin-right:0cm;margin-bottom:4.0pt;margin-left:0cm;line-height:107%;font-size:14.0pt;font-family:"Calibri","sans-serif";}h4{margin-top:12.0pt;margin-right:0cm;margin-bottom:2.0pt;margin-left:0cm;line-height:107%;font-size:12.0pt;font-family:"Calibri","sans-serif";}h5{margin-top:11.0pt;margin-right:0cm;margin-bottom:2.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";}h6{margin-top:10.0pt;margin-right:0cm;margin-bottom:2.0pt;margin-left:0cm;line-height:107%;font-size:10.0pt;font-family:"Calibri","sans-serif";} .j{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.j{}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";}span.al{font-size:12.0pt;line-height:107%; font-family:"Times New Roman","serif"}p.an{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";border: none; font-weight: bold; line-height: normal; text-align: center}span.ak{font-size:12.0pt;font-family:"Times New Roman","serif"; color:black}span.ah{font-size:12.0pt;font-family:"Times New Roman","serif"}span.ai{color:black}p.ao{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify;line-height:normal}p.ap{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify} span.af{font-size:12.0pt;line-height:107%;font-family:"Times New Roman","serif"}p.aq{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:14.0pt;text-align:justify;line-height: normal}span.ac{font-size:12.0pt;line-height:107%; font-family:"Times New Roman","serif";color:#222222}span.ab{font-size:12.0pt;line-height:107%; font-family:"Times New Roman","serif";color:#222222;background:white}p.ar{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:14.0pt;text-align:justify;line-height: normal;border:none}span.z{font-size:12.0pt;font-family:"Times New Roman","serif";color:#0563C1}p.as{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";border: none; font-weight: bold; line-height: normal; margin-bottom: 14.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 14.0pt}span.y{font-size:12.0pt;font-family:"Times New Roman","serif";color:black}table.at{margin-left:-5.75pt;border-collapse:collapse}td.v{width:263.6pt;padding:0cm 5.75pt 0cm 5.75pt} p.au{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";border: none; font-weight: bold; line-height: normal}td.t{width:138.65pt;padding:0cm 5.75pt 0cm 5.75pt}p.av{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify;line-height:normal;border:none}p.aw{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height:normal;border:none}p.ax{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";border: none; font-div: italic; line-height: normal; text-align: justify}p.ay{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";border: none; font-weight: bold; line-height: normal; text-align: justify}tr.n{height:7.0pt}td.p{width:263.6pt;padding:0cm 5.75pt 0cm 5.75pt; height:7.0pt}td.o{width:138.65pt;padding:0cm 5.75pt 0cm 5.75pt; height:7.0pt}span.l{font-size:12.0pt;line-height:107%; font-family:"Times New Roman","serif";color:#14171A} p.az{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";border: none; font-weight: bold; line-height: normal; text-align: justify; text-decoration: underline} /**/
RNS Number : 0201M
Hemogenyx Pharmaceuticals PLC
12 September 2019
 

 

 

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx" or the "Company")

 

Hemogenyx scientific advisor receives Lasker Award

H. Michael Shepard becomes second board member to win prestigious prize for medical research

 

Brooklyn, N.Y. - Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that H. Michael Shepard, a member of Henogenyx's Scientific Advisory Board, has been awarded the 2019 Lasker-DeBakey Clinical Medical Research Award. The award is given annually for biological discoveries and clinical advances that improve human health. The Lasker Awards are America's most prestigious medical research awards, the US "Nobel". This year's prize recognizes Dr. Shepard's pivotal role in the invention of Herceptin, a life-saving therapy for women with breast cancer. Herceptin is credited with reducing the risk of breast cancer recurrence and extending the survival time for patients with metastatic as well as early-stage disease.

In awarding the prize to Dr. Shepard, the Lasker Foundation said that Shepard's research "executed a new blueprint for drug discovery that has already bestowed tens of thousands of women with time and quality of life."

Upon learning of the honor, Dr. Vladislav Sandler, Hemogenyx's Chief Executive Officer, commented, "We are thrilled that Dr. Shepard's life-saving work has been recognized by this prestigious award and we are fortunate to have such a distinguished scientist advising our own organization's cutting-edge cancer research."

Shepard becomes the second Hemogenyx board member to win the prestigious prize. In 2003, Chairman of the Board Sir Marc Feldmann received the Lasker Award for his ground-breaking discovery of antibodies that block TNF, an effective treatment for rheumatoid arthritis and other autoimmune diseases.

"Michael Shepard is a pioneering scientist whose research has improved millions of lives," said Sir Marc. "I'm an admirer of his achievements and proud to be his friend and have introduced him to Hemogenyx, where his expertise will help us achieve our goals."

For further information on the award, please follow this link:

http://www.laskerfoundation.org/awards/show/herceptin-targeted-antibody-therapy-breast-cancer/

Enquiries:

Hemogenyx Pharmaceuticals plc

www.hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

[email protected]

Sir Marc Feldmann, Chairman




SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Soltan Tagiev




Peterhouse Corporate Finance Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey




US Media enquiries

Tel: +1 (323) 646-3249

Lowell Goodman

[email protected]

 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals plc ("Hemogenyx") is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly-owned US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located at its state-of-the-art research facility in New York City and a wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL, located in Liège.

Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRALBMITMBMBBFL

Quick facts: HemoGenyx Pharmaceuticals

Price: 2

Market: LSE
Market Cap: £7.22 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18